Palermo capitalizes the heart valve, cardio surgeon faces a heart attack

Since the 2024 edition, Eurovalve has made a riferimento request for the specialist who carries out the operation of valvolar surgical interventions, the city of Palermo. A obiettivo was alle impegno of Gvm Care & Research and professor Khalil Fattouch, direttore of the department of cardio-toracic and vascular surgery of the Maria Eleonora Hospital. On October 24 and 25, cardiology, cardiac surgery and anesthesiology throughout the Nh Hotel, in Foro Italico, to describe the state of the art of treating disease cases, promoted a confrontation with this new technology, treatment and diagnostic strategy Mettere de future of the future, the surgical procedure can promote a small invasion of the treatment and another technology of the future and benefit the patient.

“Secondly recent date, in Italy the heart disease is annually 13% of the population over 65 years. The latest research is 7% of the ultra 80 years of age and affects the aortic stenosis, up to 10% of mitral regurgitation, up to 15 years % of atrial or cardiac fibrillation plans to consider as a life support – by Professor Giuseppe Speziale, Cardiac Surgeon and Vice President Gvm Care & Research -: Italy and Paese In Europe, the percentage of the population is 24 .1% over the past 65 years, rising to 30% in 2050. It is a high incidence of disease that now offers a new paradigm of Eurovalve disease to guide the direction of the automotive revolution in the progress of the development of the medical world determine. Combat mortality and migrate the quality of life”.

“The program of the conference that covers a large number of arguments – the review of Fattouch, by the management of the conference – with a focus on interventions for the riparazione or the percutaneous insurance solutions, the mini-invasive technique, the ultimate new development of the mitral valve tricuspid regurgitation, the use of new medical devices and the evidence of scientific research is the last day of research and clinical testing.